Cardiovascular armamentarium in a patient with bronchopulmonary fistula

CASE REPORT

A 55-year-old patient with non-small-cell lung cancer suffered from productive cough due to bronchopulmonary fistula (BPF) following pneumectomy (figure 1A,B). First, we used vascular occlusion coils (Tornado Platin Embolization Coils, Cook, Limerick, Ireland, traditionally used for embolisation of selective

vessel supply to arteriovenous malformations) placed endobronchially in conjunction with fibrin glue application (figure 1C). However, the occluding material was expectorated only 1 week later, probably due to the size of the fistula (10 mm). Second, an Amplatzer vascular plug IV (St. Jude Medical, St. Paul, Minnesota, USA, made of nitinol wires and used for transcatheter embolisation in the peripheral vasculature and occlusion of abnormal vessel communications) was delivered into the fistula (figure 1D). A few weeks later, a bronchography could assure correct device positioning and sealing of the BPF; however, a second small BPF was visualised. Third, an Angio-Seal (St. Jude Medical, St. Paul, Minnesota, USA) vascular closure device (that quickly seals femoral artery punctures following catheter procedures) was used for the new BPF. After insertion of a J wire from the pleural space and

Figure 1 Initial CT scan (A) and bronchoscopy (B) demonstrating bronchopulmonary fistula (BPF) following right pneumectomy before closure. Chest x-ray after placement of vascular coils (C) and the Amplatzer vascular plug (D) in BPF. Angio-Seal over the J wire in the endoscopic view (E) and in view from the pleural side (F). Bronchoscopic view of the Angio-Seal anchor after BPF closure (G). Arrow=BPF, circle=closure device, arrow head=port, x=the bronchoscope.

Learning points

- Endobronchial closure of bronchopulmonary fistula is a safe and effective method, at least in selected patients.
- Combined use of different devices may be necessary.

snaring it via the bronchoscope (figure 1E), the Angio-Seal was placed and the collagen plug was directed into the fistula and deployed under bronchoscopic guidance (figure 1F,G). After 2 months, the patient remained well, and the fistulae were clinically closed.

Jens Buermann,¹ Dirk Skowasch,² Kai E Wilhelm³

¹Department of Surgery, University of Bonn, Bonn, Germany; ²Department of Internal Medicine II, University of Bonn, Bonn, Germany; ³Department of Radiology, University of Bonn, Bonn, Germany

Correspondence to Dr Dirk Skowasch, Department of Internal Medicine II—Cardiology/Pneumology, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany; dirk.skowasch@ukb.uni-bonn.de

JB and DS contributed equally to this work.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Received 16 December 2011

Accepted 6 February 2012

Published Online First 3 March 2012

Thorax 2012;**67**:847–848. doi:10.1136/thoraxjnl-2011-201524

Journal club

CFTR potentiator for cystic fibrosis

This multicentre, double blinded, randomised controlled trial assessed the efficacy of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) protein potentiator.

The primary outcome of the trial was the change in the forced expiratory volume in 1 s (FEV₁). The secondary outcomes were time to the first pulmonary exacerbation and subject-reported respiratory symptoms. The trial included 161 subjects who were 12 years of age or above with the G551D mutation.

The study showed a treatment effect of 10.6% in FEV₁ (p<0.001) in patients with a starting FEV₁ <70% predicted. There was a 55% reduction in the risk of pulmonary exacerbation and a statistically significant improvement in subject-reported respiratory symptoms by 48 weeks. The study showed no significantly increased rate of adverse effects or dropout rate associated with ivacaftor. The study was not powered to assess the treatment effects in different demographic subgroups.

The G551D mutation is present only in approximately 4%–5% of cystic fibrosis patients and produces a defective CFTR protein which localises onto the epithelial cell surfaces. In the commonest CFTR mutation, F508del, the CFTR protein is however unable to reach the cell surfaces. Ivacaftor, given its mechanism of action, is therefore not applicable to this larger patient group.

The study has shown potential clinical applications which have arisen through our increased understanding of the CFTR gene. The effects of ivacaftor beyond 48 weeks and in combination therapy for individuals with other CFTR mutations would be interesting areas of research and may broaden the clinical application of ivacaftor.

► **Ramsey BW**, Davies J, McElvaney G, *et al.* A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Eng J Med* 2011;**365**:1663–72.

Siu P Cho

Correspondence to Dr Siu P Cho, ST3, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Department of Chest Medicine, Ethelbert Road, Canterbury CT1 3NG, UK; pete.sp.cho@gmail.com

Published Online First 29 February 2012

Thorax 2012;**67**:848. doi:10.1136/thoraxjnl-2011-201512